The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
As Moderna works to broaden its mRNA platform beyond COVID-19 vaccines, the company presented pipeline progress at its Science Day event, highlighting early clinical data and upcoming trial plans in oncology and autoimmune diseases. Early data showed a clinical signal for mRNA-2808 in multiple myeloma, while Moderna aims to start a Phase 1/2 study for mRNA-4194 targeting Lynch syndrome. The company also expects Phase 1/2 data for mRNA-1195 in multiple sclerosis in the second half of 2026.
Sign in to access this content
Sign InThe update comes as Moderna's stock (MRNA) faces headwinds from declining COVID vaccine demand, closing at $61.00 on June 23, 2026, after touching a low of $58.34 and a high of $63.98 during the session. Compared with peers, Moderna trails BioNTech (BNTX) in oncology, where the latter has more advanced trials, but the focus on underserved indications such as Lynch syndrome offers potential differentiation.
Key catalysts ahead include the launch of the Phase 1/2 trial for mRNA-4194 and the H2 2026 readout for mRNA-1195. Technically, the $63.98 intraday high serves as near-term resistance, while $58.34 acts as support. With no major economic catalysts this week, the stock's direction may hinge on broader biotech sentiment and company-specific updates.